MCL1 and neoplasm: When it comes to the PI3K/AKT pathway, the dual PI3K and HDAC inhibitor CUDC-907 not only overcomes venetoclax resistance by upregulating BIM and downregulating MCL-1 but also synergizes with venetoclax to further promote tumor cell apoptosis because of its DNA damage-mediating effects in AML (48).